Additional data demonstrates positive results of pridopidine drug on Total Functional Capacity Positive results from additional analyses of PRIDE-HD and Open-HART trials with pridopidine published in a peer-reviewed journal, The Journal of Huntington's Disease. Exploratory additional efficacy data show pridopidine (45 mg bid) to be the first drug to exert a significant and clinically meaningful beneficial effect on Total Functional Capacity (TFC). Results from the Open-HART trial demonstrate the potential durability of the effect of pridopidine with less TFC decline over 5 years compared to the historical placebo group, as well as positive safety and tolerability data. Prilenia Therapeutics B.V., a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announces the publication of two articles in the peer-reviewed journal,